Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ACPs in Severe PAD/CLI by Direct Intramuscular Injection

This study has been completed.
Sponsor:
Information provided by:
TheraVitae Ltd.
ClinicalTrials.gov Identifier:
NCT00523731
First received: August 30, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted
  Purpose

Study title: A Study of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients with Critical Limb Ischemia ( ACPs-CLI )

Principle Investigator: Assoc.Prof. Pramook Mutirangura,M.D. Head of Division of Vascular Surgery , Department of Surgery, Faculty of Medicine Siriraj Hospital , Mahidol University, BKK,Thailand

Study objective : To determine the safety and efficacy of intramuscular injection of blood-borne autologous ACPs in relieving symptoms of critical limb ischemia of patients treated with maximal medical therapy and don't have intravascular or operative revascularization option.

Study Design : A pilot study , a single center, a non-randomized, open-label trial.

Total expected no. of patients : 6 main selection criteria : A. Subjects will have one or more clinical indications diagnostic of CLI such as: distal extremity pain at rest that requires the subject to use analgesics for >2 weeks; or peripheral ischemic ulcer(s); or areas of gangrene ; or non-healing ischemic ulcers AND

B. Subjects will have one or more of the following hemodynamic indicators of severe peripheral arterial occlusive disease:

I. Ankle brachial index < 0.45 II. Toe brachial index < 0.35 III. TcPO2 / TcO2 of < 40 mmHg. C. The subject is a poor candidate for standard revascularization treatment for peripheral arterial disease, based on inadequate bypass conduit, or unfavorable anatomy D. Age 18 to 80 years

Investigational Product : At D-8 250 ml of blood drawn from the patients for production of autologous EPCs or ACPs (VescellTM). On D0 ,at least 1.5 million ACPs with viability >75 % suspended in 30 ml sterile cell culture medium will be injected 1.5 cm deep and 1.5 apart by a 23 -gauge needle into the gastrocnemius muscle of the leg chosen (ischemic leg) for treatment. For injection planning a grid of 10X10 cm will be prepared and in each point 1 ml of ACPs suspension will be injected.

The study consists of 4 periods: Screening ( D-14 to-9& D-8,Treatment(D0),Acute Safety follow-up (D1&D2),Chronic follow-up (D30 & D90)period ,total follow-up of each case is 3 months.

Evaluation criteria :

Safety : no.& duration of adverse event & serious adverse event Efficacy :Attenuate CLI patients symptoms (Rest pain,Pain-free walking distance,Ulcer size &Gangrene dimension and intensity)


Condition Intervention Phase
Peripheral Arterial Disease
Critical Limb Ischemia
Procedure: Angiogenic Cell Precursors (ACPs) or Vescell TM
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study of Blood-Borne Autologous Angiogenic Cells Precursors Therapy in Patients With Critical Limb Ischemia

Resource links provided by NLM:


Further study details as provided by TheraVitae Ltd.:

Primary Outcome Measures:
  • Safety [ Time Frame: 3 months ]
  • Evaluate the safety of ACPs intramuscular injection [ Time Frame: 3 months ]
  • Efficacy [ Time Frame: 3 months ]
  • Attenuate CLI patients symptoms as [ Time Frame: 3 months ]
  • Rest pain [ Time Frame: 3 months ]
  • Pain-free walking distance [ Time Frame: 3 months ]
  • Ulcer size [ Time Frame: 3 months ]
  • Gangrene dimension and intensity [ Time Frame: 3 months ]
  • Obtain evidence for improvement of tissue perfusion due to ACPs injection [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Reduction of CLI patients hospitalization time. [ Time Frame: 3 months ]
  • Decrease CLI patient amputation rate. [ Time Frame: 3 months ]

Enrollment: 6
Study Start Date: January 2006
Study Completion Date: March 2007
Detailed Description:

Six patients with Critical Limb Ischemia (CLI) or severe Peripheral Arterial Disease(PAD) will be enrolled, screened, treated with an injection of Blood-Borne Autologous Angiogenic Cell Precursors(ACPs) in to gastrocnemius of the ischemic leg by intramuscular under regional anesthesia. Following injection.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will have one or more clinical indications diagnostic of CLI such as: distal extremity pain at rest that requires the subject to use analgesics for >2 weeks; or peripheral ischemic ulcer(s); or areas of gangrene ; or non-healing ischemic ulcers AND
  • Subjects will have one or more of the following hemodynamic indicators of severe peripheral arterial occlusive disease:

    • Ankle brachial index < 0.45
    • Toe brachial index < 0.35
    • TcPO2 / TcO2 of < 40 mmHg.
  • The subject is a poor candidate for standard revascularization treatment options for peripheral arterial disease, based on inadequate bypass conduit, or unfavorable anatomy
  • Age 18 to 80 years
  • Male or non-pregnant, non-lactating female
  • Informed consent obtained and consent form signed

Exclusion Criteria:

  • Patient having on angiography a meaningful supra popliteal occlusion that may relate to symptoms of CLI.
  • Subjects, who in the opinion of the investigator, have a vascular disease prognosis that indicates they would require a major amputation (at or above the ankle) within 4 weeks of start of treatment
  • Patient who received blood transfusions during the previous 4 weeks (to exclude the potential of non-autologous ACPs in the harvested blood).
  • Inability to communicate (that may interfere with the clinical evaluation of the patient)
  • Major operation during the preceding 3 months
  • Myocardial infarction or brain infarction or uncontrolled myocardial ischemia or persistent severe heart failure (EF< 25 %) during the preceding 3 months
  • Significant valvular disease or after valve replacement during the preceding 3 months
  • After heart transplantation
  • Severe cardiomyopathy (EF < 25 %)
  • Renal failure (creatinine > 2 mg/dl )
  • Hepatic failure
  • Anemia (lower than 11mg/dl.hemoglobin for female and lower than 12 mg/dl for male)
  • Abnormal coagulation tests [platelets, PT (INR), PTT]
  • Stroke within the preceding 3 years
  • Malignancy within the preceding 3 years
  • Concurrent chronic or acute infectious disease
  • Severe concurrent medical disease (e.g., septicemia, HIV-1,2/HBV/HCV infections, poorly controlled insulin-dependent diabetes mellitus ; HBA1c >8 % and proliferative retinopathy , systemic lupus erythematosus, multiple sclerosis, amyotrophic lateral sclerosis)
  • Chronic immunomodulating or cytotoxic drugs treatment
  • Patients who have rectal temp. above 38.40C for 2 consecutive days
  • Patient unlikely to be available for follow-up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00523731

Locations
Israel
Dr. Valentin Fulga
Tel viv, P.O.B.4049,Ness Ziona, Israel, 74410
Sponsors and Collaborators
TheraVitae Ltd.
Investigators
Principal Investigator: Pramook Mutirangura, M.D. Vascular Surgery Unit,Department of Surgery,Faculty of Medicine Siriraj Hospital,Mahidol University,BKK,Thailand
  More Information

No publications provided by TheraVitae Ltd.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00523731     History of Changes
Other Study ID Numbers: TV-003, ACPs-CLI
Study First Received: August 30, 2007
Last Updated: August 30, 2007
Health Authority: Thailand: Food and Drug Administration

Keywords provided by TheraVitae Ltd.:
Stem cells
Rest pain
claudication
chronic ischemic or non-healing ulcers
Angiogenesis
no-option cases

Additional relevant MeSH terms:
Ischemia
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Arteriosclerosis
Atherosclerosis
Cardiovascular Diseases
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014